文献速递血液净化与透析

隧道式血液透析导管的并发症:加拿大观察性队列研究

Complications From Tunneled Hemodialysis Catheters: A Canadian Observational Cohort Study.
PubMed 文献 · Am J Kidney Dis · 2019-01-12

该回顾性队列纳入5个加拿大透析项目的1,041例起始门诊维持性血液透析且使用隧道式CVC的成人患者,1年时任何CVC相关并发症风险为30%,2年为38%,CVC相关菌血症1年风险9%,CVC相关死亡6例(0.5%)。与<60岁患者相比,70-79岁和≥80岁患者CVC并发症发生率更低(HR分别为0.67和0.69)。

要点

  • 使用隧道式CVC的血液透析患者1年CVC相关并发症风险达30%,2年为38%。
  • 1年CVC相关菌血症风险为9%,是CVC相关住院最常见原因。
  • CVC相关死亡不常见,1,041例中仅6例(0.5%)。

核心结论

  • 约三分之一的血液透析患者在1至2年内使用隧道式CVC会发生并发症。
  • CVC相关菌血症1年发生率约9%,是CVC相关住院最常见原因。
  • CVC相关死亡不常见,1,041例中6例(0.5%)。
  • 该信息可用于向使用隧道式CVC的患者传达并发症风险。

研究设计与样本

  • 观察性回顾性队列研究,纳入2004至2012年5个加拿大透析项目的1,041例>18岁患者。
  • 患者起始门诊维持性血液透析使用隧道式CVC,未建立动静脉内瘘或人工血管。

主要发现

  • 1年时CVC相关菌血症、功能不良和中心静脉狭窄风险分别为9%、15%和2%。
  • 1年和2年任何CVC相关并发症风险分别为30%和38%。
  • CVC相关死亡6例(0.5%)。
  • 与<60岁患者相比,70-79岁和≥80岁患者CVC并发症发生率更低,HR分别为0.67(95%CI 0.52-0.85;P=0.001)和0.69(95%CI 0.52-0.92;P=0.01)。

临床怎么用

  • 可利用1年30%和2年38%的并发症风险向患者说明隧道式CVC的风险。
  • 应告知患者1年CVC相关菌血症风险约9%,且为CVC相关住院最常见原因。

局限性

  • 加拿大透析人群可能不能代表其他国家人群。
  • 未将CVC使用与其他血液透析血管通路类型进行比较。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

RATIONALE & OBJECTIVE: Clinical practice guidelines discourage the use of central venous catheters (CVCs) for vascular access in dialysis. However, some patients have inadequate vessels for arteriovenous fistula creation or choose to use a dialysis catheter. The risks associated with CVC use and their relationship to patient age are poorly characterized. STUDY DESIGN: Observational retrospective cohort study. SETTING & PARTICIPANTS: Cohort of 1,041 patients older than 18 years from 5 Canadian dialysis programs who initiated outpatient maintenance hemodialysis therapy with a tunneled CVC between 2004 and 2012 and who had no creation of an arteriovenous fistula or arteriovenous graft. EXPOSURES: Age, sex, body size, initiating dialysis therapy in the hospital, and comorbid conditions. OUTCOMES: CVC-related procedures, hospitalization, and death. ANALYTICAL APPROACH: Complications were reported as a cumulative risk at 1 and 2 years. Cox proportional hazards regression for recurrent events was used to evaluate risk factors for study outcomes. RESULTS: At 1 year, risks for CVC-related bacteremia, malfunction, and central stenosis were 9%, 15%, and 2%, respectively. Risks for any CVC-related complication at 1 and 2 years were 30% and 38%, respectively. Death related to CVC complications occurred in 6 of 1,041 (0.5%) patients. Compared with patients younger than 60 years, patients aged 70 to 79 and those 80 years or older experienced lower rates of CVC complications: HRs of 0.67 (95% CI, 0.52-0.85; P = 0.001) and 0.69 (95% CI, 0.52-0.92; P = 0.01), respectively. LIMITATIONS: This Canadian dialysis population may not be representative of populations in other countries. CVC use was not compared with other types of hemodialysis vascular access. CONCLUSIONS: Approximately one-third of hemodialysis patients who used tunneled CVCs during 1 to 2 years experienced complications. Bacteremia occurred in ∼9% of patients at 1 year and were the most common cause of CVC-related hospitalizations. CVC-related death was infrequent. This information could be used to communicate the risk for CVC complications to patients treated with this type of hemodialysis vascular access.

来源:Am J Kidney Dis,查看原文。版权归原作者所有。

引用

  1. Poinen K, Quinn RR, Clarke A, et al. Complications From Tunneled Hemodialysis Catheters: A Canadian Observational Cohort Study. Am J Kidney Dis. 2019. PMID: 30642607. doi:10.1053/j.ajkd.2018.10.014

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。